These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

844 related items for PubMed ID: 19358835

  • 1. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE.
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [Abstract] [Full Text] [Related]

  • 2. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B, Urban M.
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [Abstract] [Full Text] [Related]

  • 3. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
    Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE.
    Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
    [Abstract] [Full Text] [Related]

  • 4. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W.
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [Abstract] [Full Text] [Related]

  • 5. Different circulating metalloproteinases profiles in women with migraine with and without aura.
    Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
    [Abstract] [Full Text] [Related]

  • 6. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [Abstract] [Full Text] [Related]

  • 7. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B, Głowińska B, Urban M, Peczyńska J.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 May; 12(3):184-9. PubMed ID: 17020653
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.
    Anticancer Res; 2000 May; 20(2B):1311-6. PubMed ID: 10810441
    [Abstract] [Full Text] [Related]

  • 11. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY.
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM, Novaes AB, Meschiari CA, Souza SL, Palioto DB, Sorgi CA, Faccioli LH, Tanus-Santos JE, Gerlach RF.
    Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
    Szczepańska-Kostro J, Kowalewski M, Urban M, Gardziejczyk M.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Nov; 12(4):257-60. PubMed ID: 17239302
    [Abstract] [Full Text] [Related]

  • 16. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 17. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ, Lacchini R, Belo VA, Nobre YT, Tucci S, Martins AC, Tanus-Santos JE.
    Int J Impot Res; 2012 May 02; 24(1):38-43. PubMed ID: 21918531
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY.
    Am J Hypertens; 2004 Sep 02; 17(9):764-9. PubMed ID: 15363817
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.